While all the mAbs used for breast cancer treatment (trastuzumab, pertuzumab and trastuzumab emtansine) target HER2, the mAbs currently used for colorectal cancer treatment target Epidermal Growth Factor Receptor (EGFR) (cetuximab, panitumumab) or Vascular Endothelial Growth Factor (VEGF) (bevacizumab and ramucirumab). This evidence concerns the gene EGFR and breast carcinoma.